Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Psyched Wellness has contracted the National Research Council of Canada
  • The NRC of Canada was hired to provide expertise in biomedical nanotechnology
  • Work will further preliminary findings indicating anti-inflammatory and antioxidant properties and the study of potential neuroprotective roles of the AME-1 extract
  • Psyched Wellness is a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms
  • Psyched Wellness is up 2.08 per cent, trading at C$0.24 at 12:24 pm ET

Psyched Wellness has contracted the National Research Council of Canada (NRC).

The contract is divided into three objectives over a two-year period.

Work will further preliminary findings indicating anti-inflammatory and antioxidant properties in addition to the study of potential neuroprotective roles of the AME-1 extract.

Psyched Wellness is a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms.

The National Research Council of Canada pecializes in providing vital scientific and technological services to the research and industrial communities of Canada.

The NRC was hired to provide expertise in biomedical nanotechnology.

All the results of the research will belong to Psyched, and the research council does not endorse the findings or Psyched products.

“This investigative study will reveal key nutritional systematic and functional properties of the AME-1 extract. The Amanita Muscaria mushroom functional properties will be further investigated and identified in this scientific approach using modern scientific methods to help understand the functional neuroprotective and immune properties of AME-1,” said Psyched Wellness scientific advisor Brian Tancowny.

Psyched Wellness is a health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods. The company’s objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category.

Psyched Wellness is up 2.08 per cent, trading at C$0.24 at 12:24 pm ET.

More From The Market Herald

" Optimi Health (CSE:OPTI) signs psilocybin supply agreement with Halucenex Life Sciences

Optimi Health (OPTI) has announced a supply agreement with Halucenex Life Sciences Inc., a wholly-owned subsidiary of Creso Pharma of Australia.

" Revive (CSE:RVV) gets FDA OK for Bucillamine trials to treat COVID-19

Revive Therapeutics (RVV), a cannabis and psychedelic healthcare company has received feedback from the U.S. FDA to help advance Bucillamine.

" Clearmind Medicine (CSE:MIND) and SciSparc report positive results for Psychedelic Combination Treatment

Clearmind Medicine (MND) has released favourable safety profile results from its joint pre-clinical trial with SciSparc Ltd. (NASDAQ: SPRC).

" Optimi Health (CSE:OPTI) acquires catalog of psychedelic and functional mushroom genetics

Optimi Health (OPTI) has acquired a catalog of psilocybin and functional mushroom strains.